Caricamento...

New agents on the horizon in hepatocellular carcinoma

Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autore principale: Zhu, Andrew X.
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2013
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3539273/
https://ncbi.nlm.nih.gov/pubmed/23323146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834012458480
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !